Single mutation of the hepatitis E virus stands in the way of sofosbuvir drug’s effectiveness

Or­chard Ther­a­peu­tics’ ul­tra-rare dis­ease drug Len­meldy is vault­ing to the list of most ex­pen­sive drugs ever with a whole­sale ac­qui­si­tion cost of $4.25 mil­lion for

Share this article The company’s candidates ALTO-100, ALTO-202 and ALTO-300 are all developed for depression, with ALTO-100 also being developed for post-traumatic stress disorder. Image